Condition
Lymphoma, High-grade
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (2)
Trial Status
Unknown2
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05263583Phase 2Active Not Recruiting
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
NCT03479918Phase 3UnknownPrimary
R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)
NCT00554164Phase 3CompletedPrimary
Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas
NCT00385125Phase 2UnknownPrimary
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Showing all 4 trials